To OTC Journal Members:
 

Cinnergen In WalMart

The product you see pictured here is carrying EFSF for the time being, and I like the way things are shaping up. Today, just as the market opened, EFSF announced it will be shipping the product to 500 of the 3800 WalMart locations, with the remainder to begin receiving shipments by the end of June.

Anecdotally, I am hearing the product is getting to be harder to find, as demand is increasing. I am told CVS.com sells out the moment they get supplies, and EFSF is starting to gear up production to meet the increasing demand.

According to the press release, the TV commercial campaign will pick up as well, with a greater commitment to the short spots running on CNN. 

There hasn't been much more than a technical bounce in this stock of late, so my expectations are the news will take the stock to higher levels- perhaps to a new multi year high. After all, WalMart is now the largest company in the world, and the most prolific retailer on Planet Earth. 

For the sake of the stock price, I like WalMart carrying the product. However, there is something I like even better. EFSF has been publicly predicting Cinnergen would be in 20,000 retail locations by the end of June, and it appears they are well on their way to delivering on their promise. I like companies that deliver.

So, buy, sell, or hold? Here's the chart.

This is a very long term look. In fact, this chart is measured on a weekly basis, and goes back to when it first started to trade in 2003. The longer term the chart, the more predictive the model.

As you can see, this stock has basically been trending down for four years. It has never regained the $.80 level it attained in 2003. However, that long term downtrend line you see in blue is now in danger of giving way. If this stock can trade above $.505, and do so with volume and conviction, I believe it will signal a long term trend reversal, and bring some of the higher prices into the picture some of you have been suggesting. Where to? Too early to say.

At this point, it will be interesting to see whether it breaks the downtrend line, or just butts up against in for a second time. In either case, if this company keeps delivering positive fundamental developments akin to today's revelation from WalMart, eventually that downtrend line will be broken, and it's anybody's guess from there.

I have to pat myself on the back for last Friday's BLOG, stating EFSF was a strong technical in that $.37 to $.39 range. Hopefully, many of you who like this one acted.  If you have to buy it today, take a partial position and don't be afraid to act to add to it when the stock is selling off. If you want to take a profit on the surging volume associated with this news, keep the funds handy for a pullback down the road. The pullback might higher than where you sold, but it doesn't matter.

Here is the complete text of today's release for your review:
 

Subscribe

Information is power and timely information is profitable. Become informed and profit from OTC Journal Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the OTC Journal Email Newsletter on a regular basis.

To ensure newsletter delivery, you can add any additional email addresses you may have to the OTC Journal Member List. Receiving the OTC Journal Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the OTC Journal recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery.

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the OTC Journal, simply follow the instructions located at the bottom of every OTC Journal Newsletter Edition.

Go Here to view our compensation on every company we have ever covered, or visit the following web address:  http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts. MarketByte LLC has been paid a fee of $30,000 cash and 1 million newly issued restricted shares by eFoodSafety for coverage of the company. 

All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

From time to time MarketByte LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.

The editor, members of the editor's family, and/or entities with which they are affiliated aside from MarketBtye LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. Some of the companies featured in the OTC Journal pay a cash ESP fee to an affiliated technology company ranging from $2,000 to $5,000 per month for internet related technology services.

The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $310,0000 in the Longview Fund (“the Longview Limited Partnership”), a limited partnership in which the MarketByte Pension Plan is a limited partner. No one associated with the MarketByte Pension Plan has any knowledge, information, or control as to any past, present, or future investment activities of the Longview Fund.  Longview ocassoinally refers companies to MarketByte LLC for possible coverage by one of the MarketByte LLC publications, which publications include The OTCJournal.com Newsletter. Longview may or may not own shares in the companies that it so refers to MarketByte. MarketByte has no information (outside of information readily accessible to the general public such as SEC filings) as to whether Longview owns any shares in the companies that it refers to MarketByte LLC.  The above relationships should be viewed as a potential and/or actual conflict of interest by shareholders and prospective shareholders of MarketByte LLC client companies. 

The profiles, critiques, and other editorial content of the OTCjournal.com may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm. Disclaimer ID:$subst('Recip.userid') Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.  MarketByte LLC's mailing address is 4653 Carmel Mtn Rd Suite 308 #402, San Diego, CA 92130.